person · Reporting owner

RINGO WILLIAM R

Disclosed activity across 7 companies

Tapewire entity: 16993
SEC CIK: 0001238325

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216	Director	June 05, 2025	June 09, 2025
Faeth Therapeutics, Inc.SNSE · Entity 5029	Director	May 21, 2025	May 23, 2025
IMMUNE DESIGN CORP.IMDZ · Entity 158527	Director	April 02, 2019	April 04, 2019
SANGAMO THERAPEUTICS, INCSGMO · Entity 7038	Director	September 20, 2017	September 22, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ASSEMBLY BIOSCIENCES, INC.

Report date June 05, 2025 · Filed June 09, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.81 · Expires 2035-06-05	Direct	3,500	Reported balance After 2025-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-05 · Grant · Acquired 3,500 · Balance 3,500 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders.

Faeth Therapeutics, Inc.

Report date May 21, 2025 · Filed May 23, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2035-05-20	Direct	19,000	Reported balance After 2025-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-05-21 · Grant · Acquired 19,000 · Balance 19,000 F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

IMMUNE DESIGN CORP.

Report date April 02, 2019 · Filed April 04, 2019

Security / award	Ownership account	Disclosure context
Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60	Direct	Reported balance After 2019-04-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-04-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable.
Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05	Direct	Reported balance After 2019-04-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable.
Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31	Direct	Reported balance After 2019-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding.

F2: Not Applicable.

SANGAMO THERAPEUTICS, INC

Report date September 20, 2017 · Filed September 22, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	800	Ending reported balance After 2017-09-20 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-09-20 · Exercise / conversion · Acquired 31,000 · Balance 31,800 Row 2 · 2017-09-20 · Sale · Disposed 31,000 · Balance 800 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.55, inclusive. The Reporting Person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05 · Expires 2020-04-15	Direct	0	Reported balance After 2017-09-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-09-20 · Exercise / conversion · Disposed 31,000 · Balance 0 F2: The shares underlying the stock option are fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.55, inclusive. The Reporting Person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F2: The shares underlying the stock option are fully vested and exercisable.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dermira, Inc.

Report date February 20, 2020 · Filed February 24, 2020

Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-02-20 transaction · row 1 1 source row Row 1 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-06-05	Direct	Reported balance After 2020-02-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-02-20 · Disposition to issuer · Disposed 18,275 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2025-06-10	Direct	Reported balance After 2020-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-02-20 · Disposition to issuer · Disposed 8,620 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.82 · Expires 2026-06-20	Direct	Reported balance After 2020-02-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.01 · Expires 2027-06-12	Direct	Reported balance After 2020-02-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-06-12	Direct	Reported balance After 2020-02-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2029-06-03	Direct	Reported balance After 2020-02-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-02-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.

FIVE PRIME THERAPEUTICS, INC.

Report date April 05, 2021 · Filed April 19, 2021

Section 16 reporting ended · disclosed 2021-04-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-04-05 transaction · row 1 1 source row Row 1 · 2021-04-05 · Gift · Disposed 10,000 · Balance 0
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.65	Direct	Reported balance After 2021-04-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-04-16 · Disposition to issuer · Disposed 16,600 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.15	Direct	Reported balance After 2021-04-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-04-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.80	Direct	Reported balance After 2021-04-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-04-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.27	Direct	Reported balance After 2021-04-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-04-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09	Direct	Reported balance After 2021-04-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-04-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79	Direct	Reported balance After 2021-04-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-04-16 · Disposition to issuer · Disposed 34,451 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99	Direct	Reported balance After 2021-04-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-04-16 · Disposition to issuer · Disposed 46,939 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.23	Direct	Reported balance After 2021-04-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-04-16 · Disposition to issuer · Disposed 50,367 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94	Direct	Reported balance After 2021-04-16 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-04-16 · Disposition to issuer · Disposed 49,552 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31	Direct	Reported balance After 2021-04-16 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-04-16 · Disposition to issuer · Disposed 40,868 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.23	Direct	Reported balance After 2021-04-16 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2021-04-16 · Disposition to issuer · Disposed 37,998 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80	Direct	Reported balance After 2021-04-16 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2021-04-16 · Disposition to issuer · Disposed 52,408 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47	Direct	Reported balance After 2021-04-16 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2021-04-16 · Disposition to issuer · Disposed 27,769 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.

F2: Not applicable.

PFIZER INC

Report date March 31, 2010 · Filed April 01, 2010

Section 16 reporting ended · disclosed 2010-04-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom Stock Units SSPSEC Table II · derivative / convertible security	Direct	10,415	Reported balance After 2010-03-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2010-03-31 · Grant · Acquired 144 · Balance 10,415 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Filing footnotes · ownership attribution and instrument terms

F1: Each unit represents one phantom share of common stock.

F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 16, 2017 Filed Oct 17, 2017 22:30 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	Exercise / conversionStock Option (right to buy) · Derivative	1,000	$0.00 Strike: $7.20	$0.00	Disclosure SEC source: 0001144204-17-052886 · tv477078_4.xml · derivative · entry 4 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 1,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016. Read SEC document
October 16, 2017 Filed Oct 17, 2017 22:30 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	SaleCommon Stock	1,000	$33.70	$33,700.00	Disclosure SEC source: 0001144204-17-052886 · tv477078_4.xml · nonDerivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
October 16, 2017 Filed Oct 17, 2017 22:30 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	Exercise / conversionCommon Stock	1,000	$7.20	$7,200.00	Disclosure SEC source: 0001144204-17-052886 · tv477078_4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
October 02, 2017 Filed Oct 3, 2017 19:08 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionStock Option (right to buy) · Derivative	600	$0.00 Strike: $11.65	$0.00	Disclosure SEC source: 0001209191-17-055445 · doc4.xml · derivative · entry 6 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,200 Underlying: Common Stock · 600 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and immediately exercisable. Read SEC document
October 02, 2017 Filed Oct 3, 2017 19:08 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	SaleCommon Stock	600	$40.78	$24,468.00	Disclosure SEC source: 0001209191-17-055445 · doc4.xml · nonDerivative · entry 4 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016. Read SEC document
October 02, 2017 Filed Oct 3, 2017 19:08 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionCommon Stock	600	$11.65	$6,990.00	Disclosure SEC source: 0001209191-17-055445 · doc4.xml · nonDerivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 29, 2017 Filed Oct 3, 2017 19:08 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionStock Option (right to buy) · Derivative	1,200	$0.00 Strike: $11.65	$0.00	Disclosure SEC source: 0001209191-17-055445 · doc4.xml · derivative · entry 5 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,800 Underlying: Common Stock · 1,200 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and immediately exercisable. Read SEC document
September 29, 2017 Filed Oct 3, 2017 19:08 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	SaleCommon Stock	1,200	$40.00	$48,000.00	Disclosure SEC source: 0001209191-17-055445 · doc4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016. Read SEC document
September 29, 2017 Filed Oct 3, 2017 19:08 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionCommon Stock	1,200	$11.65	$13,980.00	Disclosure SEC source: 0001209191-17-055445 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 28, 2017 Filed Oct 2, 2017 14:01 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionStock Option (right to buy) · Derivative	2,000	$0.00 Strike: $11.65	$0.00	Disclosure SEC source: 0001209191-17-054484 · doc4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 2,000 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest at a rate of one-third per year on each anniversary of October 1, 2014. Read SEC document
September 28, 2017 Filed Oct 2, 2017 14:01 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	SaleCommon Stock	2,000	$38.00	$76,000.00	Disclosure SEC source: 0001209191-17-054484 · doc4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016. Read SEC document
September 28, 2017 Filed Oct 2, 2017 14:01 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionCommon Stock	2,000	$11.65	$23,300.00	Disclosure SEC source: 0001209191-17-054484 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 20, 2017 Filed Sep 22, 2017 20:04 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	Exercise / conversionStock Option (Right to Buy) · Derivative	31,000	$0.00 Strike: $6.05	$0.00	Disclosure SEC source: 0001209191-17-053691 · doc4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,000 shares Expires 2020-04-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option are fully vested and exercisable. Read SEC document
September 20, 2017 Filed Sep 22, 2017 20:04 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	SaleCommon Stock	31,000	$14.37	$445,597.10	Disclosure SEC source: 0001209191-17-053691 · doc4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.55, inclusive. The Reporting Person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
September 20, 2017 Filed Sep 22, 2017 20:04 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	Exercise / conversionCommon Stock	31,000	$6.05	$187,550.00	Disclosure SEC source: 0001209191-17-053691 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 23, 2017 Filed Oct 17, 2017 22:30 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	GiftCommon Stock	1,000	$0.00	$0.00	Disclosure SEC source: 0001144204-17-052886 · tv477078_4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 Read SEC document
June 13, 2017 Filed Jun 15, 2017 17:11 UTC	Dermira, Inc. DERM · Entity 11896	GrantRestricted Stock Unit · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-17-002279 · primarydocument.xml · derivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: The RSU will vest 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document
June 13, 2017 Filed Jun 15, 2017 17:11 UTC	Dermira, Inc. DERM · Entity 11896	GrantDirector Stock Option (right to buy) · Derivative	6,000	$0.00 Strike: $28.01	$0.00	Disclosure SEC source: 0001562180-17-002279 · primarydocument.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document
June 05, 2017 Filed Jun 7, 2017 22:00 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $7.20	$0.00	Disclosure SEC source: 0001140361-17-024392 · doc1.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-04 F1 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vest in monthly installments upon completion of each month of Board service over a one year period. Read SEC document
June 01, 2017 Filed Jun 5, 2017 20:31 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $25.96	$0.00	Disclosure SEC source: 0001144204-17-031031 · v468317_4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-06-01 F1 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (1) June 1, 2018 and (ii) the date of the Issuer's 2018 annual meeting of stockholders. Read SEC document
May 12, 2017 Filed May 16, 2017 20:31 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	SaleCommon Stock	3,461	$22.00	$76,142.00	Disclosure SEC source: 0001144204-17-027950 · v467144_4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · ownership.nature: The securities are held by the William R. Ringo Rev. Trust (the "Trust"), and the Reporting Person is the sole trustee of the Trust. Read SEC document
May 10, 2017 Filed May 12, 2017 16:24 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $29.80	$0.00	Disclosure SEC source: 0001209191-17-031947 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) May 10, 2018 or (ii) the day before the 2018 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. Read SEC document
May 10, 2017 Filed May 12, 2017 20:30 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $7.20	$0.00	Disclosure SEC source: 0001144204-17-026921 · v466891_4.xml · derivative · entry 5 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 5,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/3 of this option vested on 7/11/2014, and the remaining 2/3 vested in equal installments on 7/11/2015 and 7/11/2016. This option was fully vested as of 7/11/2016. Read SEC document
May 10, 2017 Filed May 12, 2017 20:30 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	GiftCommon Stock	3,461	$0.00	$0.00	Disclosure SEC source: 0001144204-17-026921 · v466891_4.xml · nonDerivative · entry 4 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 3,461 F2 · ownership.nature: The securities are held by the Trust and the Reporting Person is the sole trustee of the Trust. Read SEC document
May 10, 2017 Filed May 12, 2017 20:30 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	GiftCommon Stock	3,461	$0.00	$0.00	Disclosure SEC source: 0001144204-17-026921 · v466891_4.xml · nonDerivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 F1 · shares: This transaction involved a gift of securities by the Reporting Person to the Reporting Person's revocable trust, the William R. Ringo Rev. Trust (the "Trust"). The reporting Person is the sole trustee of the Trust. Read SEC document
May 10, 2017 Filed May 12, 2017 20:30 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	Tax withholdingCommon Stock	1,539	$23.39	$35,997.21	Disclosure SEC source: 0001144204-17-026921 · v466891_4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,926 Read SEC document
May 10, 2017 Filed May 12, 2017 20:30 UTC	ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216	Exercise / conversionCommon Stock	5,000	$7.20	$36,000.00	Disclosure SEC source: 0001144204-17-026921 · v466891_4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2017 Filed May 3, 2017 16:06 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionDirector Stock Option (right to buy) · Derivative	500	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001562180-17-001701 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,275 Underlying: Common Stock · 500 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/36th of the shares underlying the option vest each month from the vesting commencement date of 7/25/2014, subject to the reporting person's continuous status as a Service Provider on the applicable vesting date. Read SEC document
May 01, 2017 Filed May 3, 2017 16:06 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	500	$34.06	$17,030.00	Disclosure SEC source: 0001562180-17-001701 · primarydocument.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
May 01, 2017 Filed May 3, 2017 16:06 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionCommon Stock	500	$16.00	$8,000.00	Disclosure SEC source: 0001562180-17-001701 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 03, 2017 Filed Apr 4, 2017 17:38 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionDirector Stock Option (right to buy) · Derivative	500	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001562180-17-001442 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,775 Underlying: Common Stock · 500 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/36th of the shares underlying the option vest each month from the vesting commencement date of 7/25/2014, subject to the reporting person's continuous status as a Service Provider on the applicable vesting date. Read SEC document
April 03, 2017 Filed Apr 4, 2017 17:38 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	500	$34.03	$17,015.00	Disclosure SEC source: 0001562180-17-001442 · primarydocument.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
April 03, 2017 Filed Apr 4, 2017 17:38 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionCommon Stock	500	$16.00	$8,000.00	Disclosure SEC source: 0001562180-17-001442 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2017 Filed Mar 1, 2017 20:44 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionStock Option (right to buy) · Derivative	500	$0.00 Strike: $11.65	$0.00	Disclosure SEC source: 0001209191-17-016207 · doc4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 500 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest at a rate of one-third per year on each anniversary of October 1, 2014. Read SEC document
March 01, 2017 Filed Mar 1, 2017 20:44 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	SaleCommon Stock	500	$46.73	$23,365.00	Disclosure SEC source: 0001209191-17-016207 · doc4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016. Read SEC document
March 01, 2017 Filed Mar 1, 2017 20:44 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionCommon Stock	500	$11.65	$5,825.00	Disclosure SEC source: 0001209191-17-016207 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2017 Filed Mar 2, 2017 19:12 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionDirector Stock Option (right to buy) · Derivative	500	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001562180-17-001068 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,275 Underlying: Common Stock · 500 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/36th of the shares underlying the option vest each month from the vesting commencement date of 7/25/2014, subject to the reporting person's continuous status as a Service Provider on the applicable vesting date. Read SEC document
March 01, 2017 Filed Mar 2, 2017 19:12 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	500	$35.09	$17,547.00	Disclosure SEC source: 0001562180-17-001068 · primarydocument.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.09 to $35.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 01, 2017 Filed Mar 2, 2017 19:12 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionCommon Stock	500	$16.00	$8,000.00	Disclosure SEC source: 0001562180-17-001068 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2017 Filed Feb 16, 2017 16:00 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionDirector Stock Option (right to buy) · Derivative	500	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001562180-17-000739 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,775 Underlying: Common Stock · 500 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/36th of the shares underlying the option vest each month from the vesting commencement date of 7/25/2014, subject to the reporting person's continuous status as a Service Provider on the applicable vesting date. Read SEC document
February 15, 2017 Filed Feb 16, 2017 16:00 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	500	$32.00	$16,000.00	Disclosure SEC source: 0001562180-17-000739 · primarydocument.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 15, 2017 Filed Feb 16, 2017 16:00 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionCommon Stock	500	$16.00	$8,000.00	Disclosure SEC source: 0001562180-17-000739 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 01, 2017 Filed Feb 1, 2017 18:31 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionStock Option (right to buy) · Derivative	500	$0.00 Strike: $11.65	$0.00	Disclosure SEC source: 0001209191-17-006855 · doc4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 500 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest at a rate of one-third per year on each anniversary of October 1, 2014. Read SEC document
February 01, 2017 Filed Feb 1, 2017 18:31 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	SaleCommon Stock	500	$46.17	$23,085.00	Disclosure SEC source: 0001209191-17-006855 · doc4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016. Read SEC document
February 01, 2017 Filed Feb 1, 2017 18:31 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionCommon Stock	500	$11.65	$5,825.00	Disclosure SEC source: 0001209191-17-006855 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 04, 2017 Filed Jan 4, 2017 17:08 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionDirector Stock Option (right to buy) · Derivative	500	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001562180-17-000159 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,275 Underlying: Common Stock · 500 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/36th of the shares underlying the option vest each month from the vesting commencement date of 7/25/2014, subject to the reporting person's continuous status as a Service Provider on the applicable vesting date. Read SEC document
January 04, 2017 Filed Jan 4, 2017 17:08 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	500	$32.00	$16,000.00	Disclosure SEC source: 0001562180-17-000159 · primarydocument.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
January 04, 2017 Filed Jan 4, 2017 17:08 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionCommon Stock	500	$16.00	$8,000.00	Disclosure SEC source: 0001562180-17-000159 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 04, 2017 Filed Jan 6, 2017 21:47 UTC	IMMUNE DESIGN CORP. IMDZ · Entity 158527	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $5.60	$0.00	Disclosure SEC source: 0001209191-17-002812 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: The shares underlying the option will become fully vested on January 4, 2018, subject to the Reporting Person's continuous service through such date. Read SEC document
January 03, 2017 Filed Jan 3, 2017 18:32 UTC	FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595	Exercise / conversionStock Option (right to buy) · Derivative	500	$0.00 Strike: $11.65	$0.00	Disclosure SEC source: 0001209191-17-000448 · doc4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 500 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vest at a rate of one-third per year on each anniversary of October 1, 2014. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.